April 30, 2019 / 5:22 AM / 3 months ago

BRIEF-Novartis - Sandoz Signs Trastuzumab Biosimilar Agreement With Eirgenix

April 30 (Reuters) - Novartis AG's Sandoz unit:

* SANDOZ ENTERS AGREEMENT FOR PROPOSED TRASTUZUMAB BIOSIMILAR, CURRENTLY IN PHASE III DEVELOPMENT, TO TREAT SELECTED HER2-POSITIVE CANCER TUMORS

* SANDOZ ENTERS AGREEMENT FOR PROPOSED TRASTUZUMAB BIOSIMILAR, CURRENTLY IN PHASE III DEVELOPMENT, TO TREAT SELECTED HER2-POSITIVE CANCER TUMORS

* COLLABORATION COVERS PROPOSED TRASTUZUMAB BIOSIMILAR IN PHASE III DEVELOPMENT FOR HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE (HER2+) BREAST AND GASTRIC TUMORS

* PER LICENCE AGREEMENT, EIRGENIX, INC IS RESPONSIBLE FOR DEVELOPMENT AND MANUFACTURING

* SANDOZ HAS RIGHT TO COMMERCIALIZE IN ALL MARKETS EXCEPT CHINA AND TAIWAN

* EIRGENIX WILL RECEIVE AN UPFRONT PAYMENT ON SIGNING, MILESTONE PAYMENTS, AND IS ENTITLED TO RECEIVE PROFIT SHARE PAYMENTS FOR SALES IN TERRITORIES

* SPECIFIC TERMS OF AGREEMENT ARE CONFIDENTIAL Source text: [reut.rs/2LdnJOd] Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below